CatSci Ltd, an award-winning innovation partner for medicines development, are pleased to be attending the 10th Annual Oligo Networking Event – Continuing Excellence in Oligo Discovery & Development. The in-person oligonucleotide conference will take place on Novartis Campus, in Basel.
Dr Nigel Richardson, CatSci’s Director of New Modalities will be attending the event. Nigel has decades of experience in the oligonucleotides space, having previously led GSK’s oligonucleotide therapy for Duchenne Muscular Dystrophy into the final stages of development and regulatory submission.
CatSci recently launched our oligonucleotide capability and have opened our state-of-the-art oligonucleotide laboratory, based in our Cardiff site. Oligonucleotides have the potential to treat previously untreatable illnesses, and our in-depth understanding of these complex molecules will enable us to accelerate the development and manufacturing of life-changing RNA therapeutics. Our new oligonucleotides capability allows us to synthesise, purify, analyse and fully optimise the synthetic and downstream processes of your oligonucleotides efficiently and effectively. We can synthesis all classes of therapeutic oligonucleotides, including siRNA, ASO, Gapmers, and sgRNA, as well as GalNAc Ligands and other conjugates.